Smith & Nephew SNATS (NYSE:SNN) Stock Rating Lowered by Wall Street Zen

Smith & Nephew SNATS (NYSE:SNN) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

A number of other research analysts have also commented on the company. Canaccord Genuity Group upped their price target on Smith & Nephew SNATS from $34.00 to $35.00 and gave the stock a “hold” rating in a report on Thursday, March 5th. Royal Bank Of Canada downgraded shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research note on Monday, December 15th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Smith & Nephew SNATS has a consensus rating of “Hold” and an average price target of $36.25.

Smith & Nephew SNATS Stock Performance

NYSE SNN opened at $31.92 on Friday. The stock has a 50-day simple moving average of $34.36 and a 200 day simple moving average of $34.64. Smith & Nephew SNATS has a twelve month low of $23.91 and a twelve month high of $38.79. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.57 and a quick ratio of 1.25.

Institutional Trading of Smith & Nephew SNATS

Institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its position in Smith & Nephew SNATS by 6,663.4% in the second quarter. JPMorgan Chase & Co. now owns 1,210,655 shares of the medical equipment provider’s stock worth $37,082,000 after purchasing an additional 1,192,755 shares during the period. Todd Asset Management LLC bought a new stake in Smith & Nephew SNATS in the 3rd quarter valued at $26,319,000. Goldman Sachs Group Inc. increased its holdings in Smith & Nephew SNATS by 49.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock valued at $50,255,000 after buying an additional 583,809 shares during the period. Bank of America Corp DE raised its stake in shares of Smith & Nephew SNATS by 139.9% in the 3rd quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider’s stock valued at $35,828,000 after buying an additional 575,666 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its stake in shares of Smith & Nephew SNATS by 365.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 644,525 shares of the medical equipment provider’s stock valued at $19,742,000 after buying an additional 505,934 shares in the last quarter. 25.64% of the stock is currently owned by institutional investors.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.